Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Radiotherapy (RT)-Durvalumab Without Prophylactic Neck Irradiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase II Trial of Radiotherapy (RT)-Durvalumab Without Prophylactic Neck Irradiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms REWRITe
  • Sponsors Groupe Oncologie Radiotherapie Tete et Cou
  • Most Recent Events

    • 17 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
    • 08 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top